PT - JOURNAL ARTICLE AU - Marziano, Valentina AU - Guzzetta, Giorgio AU - Mammone, Alessia AU - Riccardo, Flavia AU - Poletti, Piero AU - Trentini, Filippo AU - Manica, Mattia AU - Siddu, Andrea AU - Stefanelli, Paola AU - Pezzotti, Patrizio AU - Ajelli, Marco AU - Brusaferro, Silvio AU - Rezza, Giovanni AU - Merler, Stefano TI - Return to normal: COVID-19 vaccination under mitigation measures AID - 10.1101/2021.03.19.21253893 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.19.21253893 4099 - http://medrxiv.org/content/early/2021/03/20/2021.03.19.21253893.short 4100 - http://medrxiv.org/content/early/2021/03/20/2021.03.19.21253893.full AB - Being unable to suppress SARS-CoV-2 transmission, the majority of countries worldwide have resorted to a mitigation approach towards COVID-19, allowing some degree of viral circulation in the population. Here, we investigate the expected outcomes of the interplay between vaccination rollout and adaptive mitigation measures constantly altering the epidemic trajectory and keeping the reproduction number around the unit. Using a novel mathematical modeling framework, we estimate that, for vaccination capacities of at least 4 daily doses administered per 1,000 inhabitants, a complete release of mitigation measures can be expected within 7 to 13 months since the start of vaccination, with a two-year cumulative incidence of deaths between 0.18 and 0.46 per 1,000 population. A heavier burden of deaths and a delayed “return-to-normal” is expected for lower vaccine capacities, if viral transmissibility exceeds by >60% the one estimated at the beginning of the pandemic, or if vaccine protection is short-lived. Failure to prioritize the elderly or a premature release of mitigation measures after vaccination of the most fragile will conspicuously increase the expected mortality. Finally, strategies oriented to prioritize the suppression of SARS-CoV-2 by maintaining strict restrictions will take a similar time as a mitigation approach, possibly resulting in acceptability issues. Persisting unknowns about the evolving epidemiology of SARS-CoV-2 variants and on the effectiveness of available and upcoming vaccines may warrant a future reassessment of these conclusions.Competing Interest StatementM.A. has received research funding from Seqirus. The funding is not related to COVID-19. All other authors declare no competing interest.Funding StatementV.M., G.G., P.Po., F.T., M.M. and S.M. acknowledge funding from EU grant 874850 MOOD (catalogued as MOOD 000). The contents of this publication are the sole responsibility of the authors and don't necessarily reflect the views of the funders.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB was needed for this studyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in the manuscript are publicly available.